Publications | USF Parkinson's Disease and Movement Disorders Center

2004

Zesiewicz, TA, ED Louis, KL Sullivan, M Menkin, PB Dunne, and RA Hauser. 2004. “Substantial Improvement in a Meige’s Syndrome Patient With Levetiracetam Treatment. Movement Disorders 2004;19:1518-1521.”. Movement Disorders.

Zesiewicz, TA, JA Strom, AR Borenstein, RA Hauser, CR Cimino, H Fontanet, C Cintron, JF Staffetti, PB Dunne, and KL Sullivan. 2004. “Heart Failure in Parkinson’s Disease: Analysis of the United States Medicare Current Beneficiary Survey. Parkinsonism Relat Disord 2004;10:417-420.”. Parkinsonism Relat Disord.

Hauser, RA. 2004. “Levodopa/Carbidopa/Entacapone Triple Combination (Stalevo). Neurology 2004;62 (Suppl 1):S64-71.”. Neurology.

Group, Parkinson Study. 2004. “A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Arch Neurol 2004;61:561-566.”. Arch Neurol.

Waters, CH, KD Sethi, RA Hauser, E Molho, and JM Bertoni. 2004. “Zydis Selegiline Reduces Off Time in Parkinson’s Disease Patients With Motor Fluctuations: A 3-Month, Randomized, Placebo-Controlled Study. Movement Disorders 2004;19:426-432.”. Movement Disorders.

Adler, CH, RA Hauser, K Sethi, JN Caviness, L Marlor, M Anderson, and JG Hentz. 2004. “Ropinirole for Restless Legs Syndrome: A Placebo-Controlled Crossover Trial. Neurology 2004;62:1405-1407.”. Neurology.

Zesiewicz, TA, SN Carter, KL Sullivan, JS Staffetti, PB Dunne, and RA Hauser. 2004. “Initial Management of Parkinson’s Disease in a Florida Community. J Applied Research 2004;4:95-98.”. J Applied Research.

2003

Zesiewicz, TA, SN Carter, KL Sullican, JS Staffetti, PB Dunne, and RA Hauser. 2003. “Initial Management of Parkinson’s Disease in a Florida Community. J Applied Research 2004;4:95-98.”. J Applied Research.

Hauser, RA, JP Hubble, and DD Truong. 2003. “Randomized Trial of the Adenosine A2A Receptor Antagonist Istradefylline in Advanced PD. Neurology 2003;61:297-303.”. Neurology.

Kase, H, S Aoyama, M Ichimura, K Ikeda, A Ishii, T Kanda, K Koga, and . 2003. “Progress in Pursuit of Therapeutic A2A Antagonists: the Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development Toward a Novel Nondopaminergic Therapy for Parkinson’s Disease.”. Neurology.